Pharming Group N.V. Form 6-K Summary
Business context and reporting period
Pharming Group N.V., a Netherlands-based global biopharmaceutical company, filed this Form 6-K for March 2023, with the accompanying press release dated March 12, 2023. The filing addresses the company’s exposure to Silicon Valley Bank entities following the FDIC receivership of Silicon Valley Bank U.S. and the intended insolvency proceedings for Silicon Valley Bank UK.
Key financial metrics and liquidity
- Total cash and cash equivalents, together with restricted cash, were approximately US$209 million as of December 31, 2022.
- Deposits included approximately US$26 million with Silicon Valley Bank U.S. and US$19 million with Silicon Valley Bank UK, or approximately US$45 million in aggregate.
- The company stated that deposits with Silicon Valley Bank U.S. were largely uninsured and deposits with Silicon Valley Bank UK largely exceeded the applicable protected limit.
- Management cited Pharming’s strong balance sheet and operating cash flows as supporting its ability to fund operating plans, convertible debt service obligations, and other material cash requirements for the next twelve months and beyond.
- The filing does not provide revenue, profit, operating cash flow, margin, or debt-balance figures for the reported period.
Material changes versus the prior comparable period
The filing does not present comparative financial statements or quantify changes versus a prior comparable period. The material event disclosed is the potential loss or delayed recovery of funds held at Silicon Valley Bank U.S. and Silicon Valley Bank UK.
Guidance, outlook, risks, and unusual items
- Pharming stated that it does not expect the bank closures and insolvency proceedings to materially affect its operating plans, convertible debt service obligations, or other material cash requirements over the next twelve months and beyond.
- The company intends to actively pursue recovery of its deposits but stated that the amount and timing of recovery remain uncertain.
- Pharming continues to monitor the situation and may be affected by the outcome and timing of U.S. and U.K. regulatory and insolvency proceedings.
- Forward-looking statements are subject to risks involving clinical and commercial developments, regulatory and technical matters, working-capital needs, cash resources, and the company’s ability to recover the affected deposits.
Investor verification points
- Verify the ultimate recovery amount and timing for the approximately US$45 million deposited with the two Silicon Valley Bank entities.
- Confirm the treatment of any unrecovered deposits, including potential impairment, insurance proceeds, or other recoveries.
- Review subsequent filings for changes to liquidity, operating cash flow, convertible debt obligations, and funding requirements.
- Assess whether the company’s stated ability to fund operations for the next twelve months and beyond remains valid after resolution of the bank proceedings.